Sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease without and after kidney transplantation
Authors:
Patrícia Kleinová 1,2; Tímea Blichová 1,2; Matej Vnučák 1,2; Karol Graňák 1,2; Monika Beliančinová 1,2; Ivana Dedinská 1,2
Authors‘ workplace:
Transplantačno-nefrologické oddelenie UNM, Martin
1; I. interná klinika JLF UK a UNM, Martin
2
Published in:
Forum Diab 2024; 13(2): 69-72
Category:
Review Article
Overview
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent the first-line treatment for diabetic kidney disease, and have also become part of the treatment algorithm for chronic kidney disease. Gliflozin have significant cardio-renoprotective effects with reduction of albuminuria and stabilization of glomerular filtration rate in patients with chronic kidney disease. Secondary effects (weight reduction, stimulation of erythropoiesis, inhibition of pro-inflammatory parameters) make SGLT2i broad-spectrum agents with the possibility of expanding prescribing restrictions. However, the benefit and safety of use in patients after kidney transplantation remains a question.
Keywords:
kidney transplantation – chronic kidney disease (CKD) – sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Sources
Mark PB, Sarafidis P, Ekart R et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant 2023; 38(11): 2444–2455. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfad112>.
Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21(1): 31–38. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.532>.
Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. [Updated 03–06–2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/books/NBK576405/>.
Skrabic R, Kumric M, Vrdoljak J et al. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines 2022; 10(10): 2458. Dostupné z DOI: <http://dx.doi.org/10.3390/biomedicines10102458>.
Rossing P, Caramori ML, Chan JCN et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102(5): 990–999. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2022.06.013>.
Demir ME, Özler TE, Merhametsiz Ö et al. The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers. Int Urol Nephrol 2023; 55(11): 2989–2999. Dostupné z DOI: <https://doi.org/10.1007/s11255–023–03645–7>.
Sánchez Fructuoso AI, Bedia Raba A, Banegas Deras E et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. Clin Kidney J 2023; 16(6): 1022–1034. Dostupné z DOI: <https://doi.org/10.1093/ckj/sfad007>.
Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021; 8: 777861. Dostupné z DOI: <http://dx.doi.org/10.3389/fmed.2021.777861>.
Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
August P. Chronic Kidney Disease – Another Step Forward. N Engl J Med 2023; 388(2): 179–180. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe2215286>.
Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.
Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.
Herrington WG, Staplin N, Wanner C et al. [The EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.
Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4):323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.
Zoznam kategorizovaných liekov 1. 9. 2023–30. 9. 2023. [21–03–2024]. Dostupné z WWW: <https://www.health.gov.sk/?zoznam-kategorizovanych-liekov>.
Ramakrishnan P, Garg N, Pabich S et al. Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients. World J Transplant 2023; 13(5): 239–249. Dostupné z DOI: <http://dx.doi.org/10.5500/wjt.v13.i5.239>.
Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Ther Adv Endocrinol Metab 2022; 13: 20420188221090001. Dostupné z DOI: <http://dx.doi.org/10.1177/20420188221090001>.
[Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group]. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024; 105(Suppl 4S): S117–S314. Dostupné z DOI: <http://dx.doi.org/0.1016/j.kint.2023.10.018>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2024 Issue 2
Most read in this issue
- Transplantation of the islets of Langerhans – present and future. First experience with islet of Langerhans transplantation in Slovakia
- Chronic kidney disease in the context of diabetes mellitus
- Obesity – overview of contemporary knowledge and its role in the context of selected cardiovascular diseases
- Actual position of metformin in the treatment of type 2 diabetes mellitus